TNF Pharmaceuticals Stock Soars 6.11% Despite 10-K Filing Delay
TNF Pharmaceuticals' stock surged 6.11% in pre-market trading on April 2, 2025, reflecting a significant uptick in investor interest and confidence in the company's prospects.
TNF Pharmaceuticals, a clinical-stage pharmaceutical company, has been making strides in developing novel therapeutic platforms. The company's MYMD-1 drug platform, which regulates the immune system to control TNF-a and other pro-inflammatory cytokines, is being developed to treat autoimmune diseases and delay aging. Additionally, the Supera-CBD platform aims to address chronic pain, addiction, and epilepsy, leveraging a synthetic derivative of cannabidiol (CBD).
Recently, TNF Pharmaceuticals announced a delay in filing its Annual Report on Form 10-K for the financial period ending December 31, 2024. This delay could be attributed to various factors, including the need for additional time to finalize financial statements or address regulatory requirements. Despite this setback, the company's focus on innovative therapeutic solutions continues to drive investor optimism.

โ๐ฐ ๐๐๐๐ ๐๐ ๐๐๐๐ ๐ ๐๐๐๐๐๐ ๐๐ ๐๐๐๐๐ ๐๐๐ ๐ฎ๐๐ ๐๐๐ ๐๐๐๐ ๐๐๐๐๐ ๐๐๐๐๐๐๐๐ ๐๐ ๐๐ ๐๐๐๐. ๐จ๐ ๐ ๐๐๐๐๐๐๐ ๐๐๐๐๐๐, ๐ฐ ๐๐ ๐๐๐๐๐๐๐ ๐๐ ๐๐๐๐ ๐ ๐๐๐๐๐ ๐๐ ๐๐๐๐๐๐ ๐ ๐๐๐๐ ๐ ๐๐๐๐๐๐๐๐ ๐๐๐๐๐๐๐๐๐, ๐๐๐๐๐๐ ๐๐๐ ๐๐๐ ๐ผ๐ฒ, ๐ผ๐บ๐จ, ๐ฐ๐๐ ๐๐, ๐ช๐๐๐๐ ๐, ๐จ๐๐๐๐๐๐๐๐, ๐๐๐ ๐ฎ๐๐๐๐๐๐. ๐ป๐๐๐๐๐๐๐, ๐๐โ๐๐ ๐๐๐๐๐๐ ๐๐ ๐๐๐ ๐๐๐๐๐ ๐๐๐๐๐๐๐๐๐๐๐๐ ๐ ๐๐๐๐๐๐๐๐. ๐ถ๐๐ ๐๐ ๐๐ ๐๐๐๐๐๐ ๐๐๐๐ ๐๐๐ ๐๐๐๐๐๐๐ ๐๐ ๐๐๐๐๐๐๐๐๐ ๐๐๐ ๐๐๐๐๐๐๐๐ ๐๐ ๐๐๐๐๐๐ ๐๐๐๐ ๐๐๐. ๐ฐ๐๐๐๐๐๐๐๐, ๐ฐ ๐๐๐ ๐๐ ๐ ๐๐๐๐๐, ๐๐๐ ๐๐๐๐๐ ๐๐๐๐๐๐ ๐๐๐ ๐๐๐๐๐๐๐๐๐ ๐๐๐๐ ๐๐๐๐๐๐๐๐๐๐๐๐๐ ๐๐๐๐ ๐ ๐๐๐๐๐ ๐๐๐๐๐, ๐ฐ ๐ ๐๐๐๐ ๐๐ ๐๐ ๐๐๐๐ ๐๐ ๐ ๐๐๐.
๐ป๐๐๐ ๐๐๐๐๐๐๐ ๐๐๐๐๐, ๐ช๐๐๐๐๐๐๐๐ ๐ฌ. ๐น๐๐๐๐๐๐, ๐๐๐ ๐๐๐๐ ๐ ๐๐๐๐๐๐๐๐ ๐๐ ๐๐. ๐พ๐๐๐ ๐๐๐ ๐๐๐๐๐๐๐๐๐๐ ๐๐๐๐ ๐๐๐ ๐๐๐๐๐๐๐, ๐๐โ๐๐ ๐๐๐๐ ๐๐๐๐ ๐๐ ๐๐๐๐ ๐๐๐๐ ๐๐๐๐๐ ๐๐๐๐ ๐๐ ๐๐๐๐ ๐ ๐๐ ๐๐๐๐ ๐๐๐ ๐๐๐๐๐๐๐๐. ๐บ๐๐ ๐๐ ๐๐๐๐๐ ๐ฎ๐๐ -๐๐๐๐ ๐๐๐ ๐๐๐ ๐๐๐๐๐๐๐ ๐๐๐๐๐๐๐๐๐ ๐๐๐๐๐๐๐๐๐๐๐๐๐ ๐๐ ๐๐๐๐. ๐ฐ๐ ๐๐๐โ๐๐ ๐๐๐๐๐๐๐ ๐๐๐ ๐ ๐๐๐ ๐๐ ๐๐๐๐๐๐๐ ๐๐๐๐ ๐๐๐๐๐๐๐๐๐ ๐๐๐๐๐๐๐๐๐, ๐ฐ ๐๐๐๐๐๐๐๐๐ ๐๐๐ ๐๐ ๐๐๐๐๐ ๐๐๐ ๐๐ ๐๐๐ ๐๐ ๐ญ๐๐๐๐๐๐๐. ๐ป๐๐๐๐ ๐๐, ๐๐๐๐๐๐ ๐๐ ๐๐๐๐๐๐๐๐๐. ๐ซ๐๐โ๐ ๐๐ ๐๐๐๐๐๐ โ๐๐๐โ๐๐ ๐๐ ๐๐๐ ๐๐๐๐๐ ๐๐๐๐๐!โ
๐ฃ๐๐'๐ ๐๐๐๐พ๐๐ ๐ป๐ ๐๐๐ฝ๐ ๐ ๐๐ ๐๐๐๐ผ๐๐ ๐๐ ๐ผ๐๐๐๐๐ ๐๐๐พ๐ ๐๐๐ ๐ฝ๐ ๐๐๐ ๐๐บ๐๐พ ๐บ ๐๐๐๐๐พ๐ ๐๐๐๐ฝ๐พ. ๐จ ๐ ๐๐๐ 30๐ ๐๐๐๐๐๐ ๐๐ ๐๐๐บ๐ฝ๐พ ๐๐ ๐๐ ๐๐๐ ๐ป๐๐ ๐พ๐๐พ๐ ๐๐๐๐ผ๐พ ๐ฌ๐๐ ๐ค๐ ๐๐๐บ๐ป๐พ๐๐ ๐ณ๐๐๐ ๐พ๐ ๐๐๐พ๐๐๐พ๐ฝ ๐๐, ๐จ ๐๐บ๐๐พ ๐ป๐พ๐พ๐ ๐๐บ๐๐๐๐ ๐๐๐๐พ ๐๐๐๐ฟ๐๐๐. ๐จ ๐๐บ๐ฝ๐พ ๐๐๐พ๐ 450๐ ๐๐๐๐ผ๐พ ๐ฎ๐ผ๐๐๐ป๐พ๐. ๐ฒ๐๐พ ๐๐ ๐บ๐ ๐๐บ๐๐ ๐บ๐๐บ๐๐ ๐บ๐ป๐ ๐พ ๐๐ ๐๐พ๐ ๐ ๐๐๐ ๐๐๐๐พ ๐บ๐ป๐๐๐ ๐๐๐๐พ๐๐๐๐๐ ๐บ๐๐ฝ ๐๐๐๐พ ๐บ ๐๐๐๐ฝ๐พ ๐๐ ๐๐๐ ๐๐ ๐๐๐บ๐ฝ๐พ ๐๐๐๐๐ ๐๐พ๐ ๐๐ ๐ถ๐๐บ๐๐๐ ๐๐ +1(563)279-8487